> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Translating In Vitro Antiviral Activity in Covid Drugs
- URL: https://www.fdaweb.com/translating-in-vitro-antiviral-activity-in-covid-drugs/
- Published: 2020-06-03T12:00:00.000Z
- Updated: 2026-09-14T16:16:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146927

FDA says that since the beginning of the Covid-19 pandemic it has been working to facilitate the development and availability of drugs for use by patients, doctors, and health systems as expeditiously as possible. In an online [paper](https://www.fda.gov/drugs/news-events-human-drugs/translating-vitro-antiviral-activity-vivo-setting-crucial-step-fighting-covid-19?utm%5Fcampaign=New%20Spotlight%20on%20CDER%20Science%3A%20Translating%20In%20Vitro%20Antiviral%20Activity&utm%5Fmedium=email&utm%5Fsource=Eloqua), CDER says several therapies are being tested in clinical trials to evaluate whether they are safe and effective in combating Covid-19.

“Significant effort by scientists to identify drugs with antiviral activity against the SARS-CoV-2 virus has led to investigations involving new drugs or FDA-approved drugs for other indications,” the agency says. “Identification of these potentially effective candidates is occurring at an unprecedented speed, and a necessary step in this process is translating *in vitro* antiviral activity to appropriate clinical dosing regimens. This step is complex and multifactorial, but essential to finding the right products, administered at the right doses, to the right patients, at the right time for successful treatment of Covid-19.”

The paper says that adequate and well-controlled clinical trials will ultimately determine appropriate treatment modalities for Covid-19 and will identify the stages of infection and disease at which these treatments are effective, with which administration routes, and at what dosing regimens. “Sound pharmacokinetic modeling and accurate *in* *vitro* to *in vivo* translation of data will be crucial for the appropriate design of dosing regimens administered in these trials,” the paper concludes.